The 36-month beta value for PHIO is at 0.85. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PHIO is 4.74M, and currently, shorts hold a 8.71% of that float. The average trading volume for PHIO on June 05, 2025 was 3.06M shares.
PHIO) stock’s latest price update
Phio Pharmaceuticals Corp (NASDAQ: PHIO)’s stock price has increased by 15.24 compared to its previous closing price of 2.10. However, the company has seen a 18.63% increase in its stock price over the last five trading sessions. zacks.com reported 2025-05-28 that PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.
PHIO’s Market Performance
PHIO’s stock has risen by 18.63% in the past week, with a monthly rise of 40.70% and a quarterly rise of 80.60%. The volatility ratio for the week is 1.99% while the volatility levels for the last 30 days are 6.51% for Phio Pharmaceuticals Corp The simple moving average for the last 20 days is 26.70% for PHIO stock, with a simple moving average of 3.96% for the last 200 days.
Analysts’ Opinion of PHIO
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PHIO reach a price target of $4. The rating they have provided for PHIO stocks is “Buy” according to the report published on August 05th, 2020.
PHIO Trading at 31.11% from the 50-Day Moving Average
After a stumble in the market that brought PHIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.28% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHIO starting from Bitterman Robert J, who purchase 3,000 shares at the price of $1.77 back on May 21 ’25. After this action, Bitterman Robert J now owns 22,449 shares of Phio Pharmaceuticals Corp, valued at $5,310 using the latest closing price.
Bitterman Robert J, the Chairman, Pres & CEO of Phio Pharmaceuticals Corp, purchase 1,200 shares at $1.78 during a trade that took place back on May 22 ’25, which means that Bitterman Robert J is holding 23,649 shares at $2,136 based on the most recent closing price.
Stock Fundamentals for PHIO
The total capital return value is set at -0.43. Equity return is now at value -76.12, with -66.67 for asset returns.
Currently, EBITDA for the company is -7.12 million with net debt to EBITDA at 2.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.58.
Conclusion
In conclusion, Phio Pharmaceuticals Corp (PHIO) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
